Tracers / 10-[11C]methoxy-20(S)-camptothecin

10-[11C]methoxy-20(S)-camptothecin

Also written as 10-[11C]methoxy-20(S)-camptothecin
Radionuclide
C-11 t½ 20.36 min
Modality
PET
Production route
—
Stage
preclinical
Syntheses indexed
1
Pan-cancer / multiple tumour typesDosimetry and biodistribution studies

What it is

Compound class
carbon-11-labeled camptothecin derivative
Target / mechanism
Topoisomerase I PMID 15993064
Clinical application
cancers PMID 15993064
Theranostic pair
—

Regulatory status

FDA
—
EMA (centralised)
—
Other approvals
—
Brand names
—

Clinical use

Typical injected activity
—
Uptake time
—

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
———30%-50%>96%—22885394
2012 Appl Radiat Isot

Need this precursor?We can point you to suppliers for 10-[11C]methoxy-20(S)-camptothecin, or handle the enquiry for you.

Get in touch

Quality control Preliminary — inferred from compound class

Ph. Eur. monograph
—
USP monograph
—
AppearancepHRCP HPLCRCP TLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrity
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release 10-[11C]methoxy-20(S)-camptothecin.

Get in touch

Notes

Added from reverse module search (stage 6); 1 article(s) with C-11.